Close

Anti-Human TNFRSF13C (XW-854)-28BBZ CAR mRNA LNP (XS-0822-YF8214)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

mRNA LNP is mRNA encapsulation in lipid nanoparticles. Creative Biolabs produces CAR mRNA LNPs with our proprietary production platform, ensuring the quality and expression efficiency. This product is anti-In vitro transcription (IVT) is the synthesis of RNA molecules. Creative Biolabs produces CAR mRNAs with our proprietary production platform, ensuring the quality and expression efficiency. This product is anti-TNFRSF13C scFv (XW-854)-28BBZ chimeric antigen receptor (CAR) mRNA which can be used for CAR expression in various immune cells. scFv (Human)-28BBZ chimeric antigen receptor (CAR) mRNA LNP which can be used for CAR expression in various immune cells. The CAR mRNA LNP can be conjugated with specific antibody for specific cell targeting.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

CAR Information

  • Target Species
  • Human
  • Clone
  • XW-854
  • Host
  • Mouse
  • CAR Construction
  • scFv-CD28-41BB-CD3ζ
  • CAR Generation
  • Third
  • CAR Signaling Description
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

CAR mRNA Properties

  • Cap
  • Cap 1
  • PolyA
  • Segmented PolyA
  • Product Type
  • CAR mRNA LNP
  • Lipid Mixture
  • Ethanolic lipid mixture of ionizable cationic lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid, or based on specific requirements.
  • Storage
  • Aliquot and store at -80°C. Avoid freeze/thaw cycles.

mRNA Quality Control

  • OD260/280
  • PASS
  • Agarose Gel Mobility
  • PASS
  • IVT Vector Sequencing
  • PASS
  • IVT Vector Enzyme Digestion
  • PASS
  • mRNA Transfection Efficiency
  • PASS
  • CAR Expression after mRNA Transfection
  • PASS

Target Information

  • Target
  • TNFRSF13C
  • Gene Name
  • TNFRSF13C
  • Full Name
  • BAFF receptor (B-cell activating factor receptor, BAFF-R)
  • Introduction
  • B cell-activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of Baff in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival.
  • Related Diseases
  • Stomach cancer
  • Alternative Names
  • TNFRSF13C; BAFF-R; BAFFR; BROMIX; CD268; CVID4; prolixin; tumor necrosis factor receptor superfamily member 13C; TNF receptor superfamily member 13C

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-Human TNFRSF13C (XW-854) h(41BB-CD28-CD3ζ) CAR mRNA Lipid Nanoparticle (LNP) (XS-0822-YF8214). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.